SML0636

SR1664

≥98% (HPLC)

• 别名: 4′-[[2,3-Dimethyl-5-[[[(1S)-1-(4-nitrophenyl)ethyl]amino]carbonyl]-1H-indol-1-yl]methyl]- [1,1′-Biphenyl]-2-carboxylic acid
• 经验公式（希尔记法）: C₃₃H₂₉N₃O₅
• CAS号: 1338259-05-4
• 分子量: 547.60
• 分類程式碼代碼: 12352200
• NACRES: NA.77

属性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 儲存條件: protect from light
• 顏色: white to beige
• 溶解度: DMSO: 15 mg/mL, clear
• 儲存溫度: −20°C
• SMILES 字串: [N+](=O)([O-])c1ccc(cc1)[C@@H](NC(=O)c2cc3c([n](c(c3C)C)Cc4ccc(cc4)c5c(cccc5)C(=O)O)cc2)C
• InChI: 1S/C33H29N3O5/c1-20-22(3)35(19-23-8-10-25(11-9-23)28-6-4-5-7-29(28)33(38)39)31-17-14-26(18-30(20)31)32(37)34-21(2)24-12-15-27(16-13-24)36(40)41/h4-18,21H,19H2,1-3H3,(H,34,37)(H,38,39)/t21-/m0/s1
• InChI 密鑰: IIJDFXNUWZTHIM-NRFANRHFSA-N

说明

生化／生理作用

SR1664 is a non-agonist PPARγ ligand and an inhibitor of Cdk5-mediated PPARγ phosphorylation. It has strong antidiabetic activity in two murine models of diabetes without the side effects normally asociated with the thiazolidinedione (TZD) antidiabetic PPARγ agonists. The TZD antidiabetics such as rosiglitazone and pioglitazone are full PPARγ agonists, but recent data have suggested that their separate activity, inhibition of the the obesity-linked PPARγ phosphorylation by Cdk5, is likely the more important activity for antidiabetic action. SR1664 has an IC₅₀ of 80 nM in a competitive binding assay, blocked the Cdk5-mediated phosphorylation of PPARγ in vitro with IC₅₀ between 20 and 200 nM and exhibited no PPARγ agonist activity.

SR1664 is a non-agonist PPARγ ligand and an inhibitor of Cdk5-mediated PPARγ phosphorylation; antidiabetic.

特點和優勢

This compound is featured on the CDKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

其他說明

Light sensitive

安全信息

• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable